The BeVigilant™ OraFusion™ System - Fast dental chairside biomarker analysis for confident oral cancer risk assessment.
)
)
As a professional dental practitioner, you will already
be aware of the dangers of oral cancer in your patients. Late-stage
oral cancer diagnosis remains a major challenge, with over 72% of cases
identified at stage III or IV and a five-year survival rate of
around 50% worldwide.
Yet 29% of dental patients present with an oral
abnormality during routine visits. Many potentially malignant lesions
look harmless in their early stages, making visual exams alone an uncertain
foundation for decision-making.
The BeVigilant™ OraFusion™ System, now being
introduced to UK dental practices by AMP UK, provides an opportunity to
approach this differently. It is the first and only real-time,
biomarker-based early oral cancer screening system available, offering
dentists a practical way to support earlier intervention and clearer clinical
pathways.
A New Standard for In-Practice Assessment
OraFusion is the only system that combines:
- A simple, non-invasive saliva test
- Detection of two specific salivary biomarkers linked to oral cancer
- Integration with clinical risk factors
- A clear ‘Monitor’ or ‘Investigate Further’ result in under 15 minutes
What this delivers in practice:
- A
structured, objective assessment that complements the visual exam
- Earlier
clarity on abnormalities that may previously have been monitored without
data
- Support
in identifying which patients genuinely need escalation
- Validated
intelligent software, tested over 3,500+ times
- Secure
cloud-based result storage for quality assurance and record keeping
For dental teams, it introduces a level of diagnostic
support that has not previously been available in-clinic.
Strengthening Preventive Care - and Building a New
Service Stream
By incorporating OraFusion, practices can offer:
- A
high-value screening service backed by measurable biomarkers
- A
clear conversation tool for patients with risk factors (tobacco, alcohol,
age >50, etc.)
- A
low-overhead revenue stream, with consistent per-test income
- A
meaningful contribution to earlier detection - something increasingly
expected in modern preventive dentistry
This positions your practice at the forefront of proactive
oral cancer screening, using technology that represents a genuine step forward
for primary dental care.
.png){kind=logo}
